Article
Oncology
D. Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James C. H. Yang, Ji-Youn Han, Maximilian J. Hochmair, Ki Hyeong Lee, Angelo Delmonte, Maria Rosario Garcia Campelo, Dong-Wan Kim, Frank Griesinger, Enriqueta Felip, Raffaele Califano, Alexander I. Spira, Scott N. Gettinger, Marcello Tiseo, Huamao M. Lin, Yuyin Liu, Florin Vranceanu, Huifeng Niu, Pingkuan Zhang, Sanjay Popat
Summary: In the final analysis of ALTA-1L study, brigatinib continued to demonstrate superior efficacy and tolerability compared to crizotinib in patients with ALK-positive advanced NSCLC, regardless of poor prognostic biomarkers. The potential survival benefit of brigatinib in patients with brain metastases warrants further investigation.
JOURNAL OF THORACIC ONCOLOGY
(2021)
Article
Oncology
Makoto Nishio, Tatsuya Yoshida, Toru Kumagai, Toyoaki Hida, Ryo Toyozawa, Tadasuke Shimokawaji, Koichi Goto, Kazuhiko Nakagawa, Yuichiro Ohe, Takashi Seto, Kentarou Kudou, Takayuki Asato, Pingkuan Zhang, Nobuyuki Yamamoto
Summary: This study evaluated the efficacy and safety of brigatinib in Japanese patients with ALK-positive NSCLC refractory to alectinib, showing clinically meaningful efficacy and consistent safety profile with broader populations. Brigatinib demonstrated antitumor activity in patients with specific secondary mutations and a significant objective response rate in alectinib-refractory patients.
JOURNAL OF THORACIC ONCOLOGY
(2021)
Article
Oncology
Wonyoung Choi, Youngnam Cho, Seog-Yun Park, Kum Hui Hwang, Ji-Youn Han, Youngjoo Lee
Summary: Genotyping CSF-cfDNA using a nanowire-based assay can effectively guide the treatment of LMC in patients with EGFR-mutant NSCLC, showing feasibility and effectiveness in this study.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Article
Oncology
Volkan Kes, Osman Sutcuoglu, Fatih Gurler, Ozan Yazici, Ahmet Ozet
Summary: Brigatinib is a novel and potent tyrosine kinase inhibitor used as third-generation therapy for ALK rearrangement positive NSCLC, showing highly effective anti-tumor effects on brain metastasis. While the adverse effects are manageable, limited data is available on its effects on the immune system.
CURRENT PROBLEMS IN CANCER
(2021)
Article
Oncology
Michael J. Hanley, David Kerstein, Meera Tugnait, Narayana Narasimhan, Thomas C. Marbury, Karthik Venkatakrishnan, Neeraj Gupta
Summary: This study investigated the effect of chronic hepatic impairment on the pharmacokinetics of brigatinib, a medication used for the treatment of ALK-positive non-small cell lung cancer. The results showed that mild or moderate hepatic impairment did not significantly affect the metabolism of brigatinib, but severe impairment led to increased metabolism. No dose adjustment is required for patients with mild or moderate impairment, but the dose should be reduced by approximately 40% for patients with severe impairment.
INVESTIGATIONAL NEW DRUGS
(2023)
Article
Oncology
Sanjay Popat, Odd Terje Brustugun, Jacques Cadranel, Enriqueta Felip, Marina Chiara Garassino, Frank Griesinger, Aslaug Helland, Maximilian Hochmair, Maurice Perol, Nawal Bent-Ennakhil, Christian Kruhl, Silvia Novello
Summary: The UVEA-Brig study analyzed data from 104 ALK-positive mNSCLC patients treated with brigatinib, showing an overall response rate of approximately 39.8%, a median PFS of around 11.3 months, and a median OS of about 23.3 months. Some patients discontinued brigatinib treatment due to adverse events, while others received systemic therapy post-brigatinib, including ALK inhibitors.
Review
Oncology
Ling Peng, Liping Zhu, Yilan Sun, Justin Stebbing, Giovanni Selvaggi, Yongchang Zhang, Zhentao Yu
Summary: ALK alterations in non-small cell lung cancer can be effectively treated with various ALK-targeted drugs. These drugs have shown good results in prolonging progression-free survival, but responses are often not durable and resistance can occur.
FRONTIERS IN ONCOLOGY
(2022)
Review
Pharmacology & Pharmacy
Sheridan M. Hoy
Summary: Brigatinib, an oral ALK and ROS1 tyrosine kinase inhibitor, has shown significant improvements in PFS, OR rate, and intracranial OR rate compared to crizotinib in the ALTA-1L study, expanding first-line treatment options for patients with advanced ALK-positive NSCLC.
Review
Oncology
Julien Mazieres, Helene Vioix, Boris M. Pfeiffer, Rhiannon I. Campden, Zhiyuan Chen, Bart Heeg, Alexis B. Cortot
Summary: METex14 skipping is a rare oncogenic driver in non-small-cell lung cancer and targeted therapy with MET tyrosine kinase inhibitors has been approved for its treatment. A systematic literature review found that the median frequency of METex14 skipping was 2.0% in unselected NSCLC patients and 2.4% in adenocarcinoma or nonsquamous subgroups. MET TKIs appeared to have higher efficacy outcomes for METex14 skipping NSCLC patients, but direct comparisons with chemotherapy or immunotherapy regimens were lacking.
CLINICAL LUNG CANCER
(2023)
Article
Hematology
Nina Prokoph, Jamie D. Matthews, Ricky M. Trigg, Ivonne A. Montes-Mojarro, G. A. Amos Burke, Falko Fend, Olaf Merkel, Lukas Kenner, Birgit Geoerger, Robert Johnston, Matthew J. Murray, Charlotte Riguad, Laurence Brugieres, Suzanne D. Turner
Summary: ALK-positive anaplastic large-cell lymphoma (ALCL) is a T-cell malignancy driven by the oncogenic ALK gene, accounting for 15% of pediatric non-Hodgkin lymphoma. Patients with central nervous system (CNS) relapse have poor prognosis and current treatment options are limited. Brigatinib, a second-generation ALK inhibitor, shows potential as a future therapeutic option for aggressive pediatric ALK-positive ALCL.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Lan Hou, Xin Chen, Gang Qiu, Xuejiao Qi, Yueli Zou, Junying He, Hui Bu
Summary: This study investigated the protein profiles of exosomes in cerebrospinal fluid (CSF) as a liquid biopsy for the detection of leptomeningeal carcinomatosis (LC) in non-small cell lung cancer (NSCLC) patients. The research found a potential indicator, FN1, that may classify LC and NSCLC. The findings suggest that the extracellular matrix (ECM) and epithelial-mesenchymal transition (EMT) play important roles in the process of LC. These results have promising implications for the early prediction and diagnosis of LC.
JOURNAL OF NEURO-ONCOLOGY
(2023)
Article
Oncology
Lan Hou, Xin Chen, Gang Qiu, Xuejiao Qi, Yueli Zou, Junying He, Hui Bu
Summary: This study investigates the application of label-free and PRM-based proteomics in detecting key proteins related to leptomeningeal carcinomatosis (LC). FN1 may serve as a potential indicator to classify LC and non-small cell lung cancer (NSCLC). The extracellular matrix (ECM) and epithelial-mesenchymal transition (EMT) play important roles in the process of LC. These findings show promise for early prediction and diagnosis of LC.
JOURNAL OF NEURO-ONCOLOGY
(2023)
Article
Oncology
Kai He, David Berz, Shirish M. Gadgeel, Wade T. Iams, Debora S. Bruno, Collin M. Blakely, Alexander I. Spira, Manish R. Patel, David M. Waterhouse, Donald A. Richards, Anthony Pham, Robert Jotte, David S. Hong, Edward B. Garon, Anne Traynor, Peter Olson, Lisa Latven, Xiaohong Yan, Ronald Shazer, Ticiana A. Leal
Summary: The combination of sitravatinib and nivolumab showed antitumor activity and manageable safety profile in patients with nonsquamous NSCLC.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Medicine, General & Internal
J. R. Brown, B. Eichhorst, P. Hillmen, W. Jurczak, M. Kazmierczak, N. Lamanna, S. M. O'Brien, C. S. Tam, L. Qiu, K. Zhou, M. Simkovic, J. Mayer, A. Gillespie-Twardy, A. Ferrajoli, P. S. Ganly, R. Weinkove, S. Grosicki, A. Mital, T. Robak, A. Osterborg, H. A. Yimer, T. Salmi, M. -D. -Y. Wang, L. Fu, J. Li, K. Wu, A. Cohen, M. Shadman
Summary: In a multinational phase 3 trial, zanubrutinib was found to be superior to ibrutinib in treating relapsed or refractory CLL or SLL, with better efficacy and fewer side effects.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Tatsuya Yoshida, Toru Kumagai, Ryo Toyozawa, Ryohei Katayama, Makoto Nishio, Takashi Seto, Koichi Goto, Nobuyuki Yamamoto, Yuichiro Ohe, Kentarou Kudou, Takayuki Asato, Pingkuan Zhang, Kazuhiko Nakagawa
Summary: The J-ALTA study evaluated the efficacy and safety of Brigatinib in Japanese patients with advanced ALK+ non-small-cell lung cancer (NSCLC). The results showed that Brigatinib had favorable efficacy in these patients, making it an important treatment option.
Letter
Oncology
Maxime Fouchard, Helene Jantzem, Gilles Quere, Renaud Descourt, Gilles Robinet, Pierre-Guillaume Poureau
EUROPEAN JOURNAL OF CANCER
(2019)
Article
Oncology
Aida Sampera, Francisco Javier Sanchez-Martin, Oriol Arpi, Laura Visa, Mar Iglesias, Silvia Menendez, Elisabeth Gaye, Alba Dalmases, Sergi Clave, Mariona Gelabert-Baldrich, Thomas Tuxen Poulsen, Michael Kragh, Beatriz Bellosillo, Joan Albanell, Ana Rovira, Clara Montagut
MOLECULAR CANCER THERAPEUTICS
(2019)
Article
Oncology
Renaud Descourt, Maurice Perol, Gaelle Rousseau-Bussac, David Planchard, Bertrand Mennecier, Marie Wislez, Alexis Cortot, Florian Guisier, Loick Galland, Pascal Do, Roland Schott, Eric Dansin, Jennifer Arrondeau, Jean-Bernard Auliac, Christos Chouaid
Article
Respiratory System
F. Gadby, R. Descourt, G. Robinet, G. Quere, S. Gouva, C. Roge, F. Couturaud, C. Chouaid
REVUE DES MALADIES RESPIRATOIRES
(2020)
Article
Oncology
Karim Amrane, Margaux Geier, Romain Corre, Herve Lena, Guillaume Leveiller, Florence Gadby, Regine Lamy, Jean-Louis Bizec, Eric Goarant, Gilles Robinet, Sylvie Gouva, Gilles Quere, Ronan Abgral, Ulrike Schick, Cyril Bernier, Christos Chouaid, Renaud Descourt
Article
Oncology
Mateo Sanchis-Borja, Charles Ricordel, Anne Marie Chiappa, Jose Hureaux, Luc Odier, Gaelle Jeannin, Renaud Descourt, Radj Gervais, Isabelle Monnet, Jean-Bernard Auliac, Christos Chouaid
Article
Oncology
Margaux Geier, Renaud Descourt, Romain Corre, Guillaume Leveiller, Regine Lamy, Eric Goarant, Jean-Louis Bizec, Cyril Bernier, Gilles Quere, Karim Amrane, Elisabeth Gaye, Francois Lucia, Emilie Burte, Christos Chouaid, Gilles Robinet
Article
Oncology
Philippe Thuillier, Claire Joly, Zarrin Alavi, Genevieve Crouzeix, Renaud Descourt, Gilles Quere, Veronique Kerlan, Nathalie Roudaut
Summary: This study suggested that TD induced by Nivolumab appears to be an independent predictive factor of survival, irrespective of TD severity and subtype.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Oncology
Mael Domblides, Margaux Geier, Chantal Decroisette, Renaud Descourt
Summary: Durvalumab, as a humanized monoclonal antibody targeting PD-L1, has shown antitumor activity in patients with NSCLC. However, it can also lead to immune-related adverse events, such as reversible bronchiolitis and bronchiectasis, which were previously considered irreversible.
Article
Oncology
Margaux Geier, Helene Babey, Lucie Monceau-Baroux, Gilles Quere, Renaud Descourt, Divi Cornec, Gilles Robinet
Summary: Vascular acrosyndromes such as digital ischemia can occur in NSCLC patients treated with antimetabolites, potentially requiring amputation. The cause may involve a multifactorial mechanism, including an autoimmune process.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Renaud Descourt, Maurice Perol, Gaelle Rousseau-Bussac, David Planchard, Bertrand Mennecier, Marie Wislez, Jacques Cadranel, Alexis Benjamin Cortot, Florian Guisier, Loick Galland, Pascal Do, Roland Schott, Eric Dansin, Jennifer Arrondeau, Jean-Bernard Auliac, Margaux Geier, Christos Chouaid
Summary: This analysis evaluates the efficacy of brigatinib in ALK(+) advanced non-small cell lung cancer patients, with a focus on post-brigatinib lorlatinib efficacy. The results show that brigatinib is effective in heavily pretreated patients and lorlatinib demonstrates activity after brigatinib.
Article
Immunology
Eloise Philippe, Aude Barnier, Juliette Menguy, Gilles Robinet, Gilles Quere, Francis Couturaud, Renaud Descourt
Summary: HSP is a syndrome that commonly occurs in children and is often infection-related, while in adults it is more often associated with neoplasms. This case report describes HSP associated with locally advanced lung squamous cell carcinoma, with active glomerulonephritis identified on kidney biopsy, treated with systemic corticosteroids and achieving partial response to chemoradiotherapy. Consolidation immunotherapy with PD-(L)1 inhibitor was discontinued due to the autoimmune nature of HSP, and long-term corticosteroid therapy was continued. Further studies are needed to evaluate the impact of anti-PD-(L)1 immunotherapies on autoimmune manifestations.
CASE REPORTS IN IMMUNOLOGY
(2021)
Article
Medicine, General & Internal
Paul Bore, Renaud Descourt, Luc Ollivier, Pierre-Yves Le Roux, Ronan Abgral
FRONTIERS IN MEDICINE
(2018)
